200-year-old condom decorated with erotic art goes on display in Amsterdam's Rijksmuseum
THE HAGUE, Netherlands — The Netherlands' national museum has a new object on display that merges art with Amsterdam's infamous Red Light District: a nearly 200-year-old condom, emblazoned with erotic art.
The Rijksmuseum said in a statement that the playful prophylactic, believed to be made around 1830 from a sheep's appendix, 'depicts both the playful and the serious side of sexual health.'
It is part of an exhibition called 'Safe Sex?' about 19th century sex work that opened on Tuesday.
The condom, possibly a souvenir from a brothel, is decorated with an erotic image of a nun and three clergymen.
The phrase 'This is my choice' is written along the sheath in French. According to the museum, this is a reference to the Pierre-Auguste Renoir painting 'The Judgment of Paris,' which depicts the Trojan prince Paris judging a beauty contest between three goddesses.
The condom is on display until the end of November.
Written by Molly Quell, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 days ago
- CTV News
New memorial pedestals unveiled in Victoria Park
The Royal United Services Institute (RUSI) unveiled two new memorial pedestals in Victoria Park that were designed to provide education about the events that shaped Canadian military history. The two pedestals unveiled on Thursday will honour the Second World War veterans of the liberation of the Netherlands on one and the other recognizes the Royal Canadian Navy in Korea, bringing the new total of pedestals to 36. One of the pedestals honours the Second World War veterans of the liberation of the Netherlands and the other and the other recognizes the Royal Canadian Navy in Korea, bringing the new total of pedestals to 36. The 'Pedestal Project' was brought to life by the President of RUSI and veteran Brad Hrycyna. 'I wanted to honour those who gave their lives for the safety of this country we all love so much, who ended up giving up the ultimate sacrifice,' he said. Hyrcyna has spent 37 years serving in the military, and over a decade as the RUSI President, and now wants to share his passion for military education that he learned at a young age. 'When I was in school, it was veterans of the wars who would come and tell us about their experiences and why we would never want to, ever repeat that and why peace is so precious,' he said. Bernadette McIntyre Lieutenant Governor of Saskatchewan Bernadette McIntyre at the unveiling of two new military pedestals in Victoria Park on Thursday. (Brittany Poitras / CTV News) The Lieutenant Governor of Saskatchewan Bernadette McIntyre was amongst the decorated military officials at the event and expressed how the unveiled pedestals 'tell the story of our wonderful veterans who gave up so much for our freedom.' 'It's so important for generation after generation to remember and recognize how normal citizens of Saskatchewan had the courage to go and fight for our freedom,' she went on to say. Hyrcyna says he will continue to push for military education in the form of monuments. While he does face a large financial barrier, he stated he is still determined to continue his work. 'We could easily do another six pedestals, which would cost is in the neighborhood of 15 or $16,000,' said the RUSI president. The memorial pedestals are made from limestone and are expected to be providing military education for the next generations to come.
National Post
05-08-2025
- National Post
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Article content AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland — Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Article content Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. Article content 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' Article content The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. Article content This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. Article content *Entyvio® is a registered trademark of Takeda. Article content About Polpharma Biologics: Article content Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Article content Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Article content Learn more at Article content Article content About Fresenius Kabi: Article content As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Article content . Article content This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Article content Disclaimer Article content This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy. Article content Article content Article content Article content Article content
Globe and Mail
01-08-2025
- Globe and Mail
Unlocking ROI in Medical Imaging: The Strategic Growth of the Global MRI Systems Market
"The key players profiled in the MRI systems market are Siemens Healthineers (Germany), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), FUJIFILM Corporation (Japan), Canon Inc. (Japan), Fonar Corporation (US)" Browse 226 market data Tables and 56 Figures spread through 259 Pages and in-depth TOC on "MRI Systems Market by Architecture (Open, Closed), Field Strength (High Field MRI Systems & Low Field MRI Systems), Design (Portable MRI Systems, Fixed/Stationary MRI Systems), End User (Hospitals, Diagnostic Clinic), Region - Global Forecast to 2030 Why MRI Systems Are a Smart Long-Term Investment As the healthcare industry undergoes a paradigm shift toward precision medicine and value-based care, Magnetic Resonance Imaging (MRI) has emerged as a cornerstone of diagnostic excellence. Forecasted to grow from USD 6.15 billion in 2024 to USD 9.01 billion by 2030, the MRI systems market offers robust opportunities for healthcare providers, OEMs, and strategic investors alike. For C-level executives, the MRI market represents more than just imaging hardware—it's a long-term investment in AI-enabled diagnostics, faster clinical workflows, and improved patient outcomes. With a CAGR of 6.5%, the sector is primed for innovation-led expansion and solid ROI. Market Snapshot: A Growing Industry with Predictable ROI 2024 Market Size: USD 6.15 Billion 2025 Projection: USD 6.56 Billion 2030 Forecast: USD 9.01 Billion CAGR: 6.5% (2024–2030) Driving Forces: Rise in neurological and musculoskeletal conditions Global aging population Increasing oncology imaging requirements Advancements in ultra-high-field MRI Favorable regulatory and reimbursement environments High-Value Applications: Brain & Neurological MRI Lead the Charge According to market research, brain and neurological MRI is the largest and fastest-growing application segment. This growth is driven by the surge in neurodegenerative disorders such as Alzheimer's, Parkinson's, epilepsy, and stroke. For hospital executives and diagnostic center owners, investing in neuro-MRI systems ensures better diagnostic precision, faster patient throughput, and enhanced clinical reputation—all critical ROI levers. Key ROI Insights: Faster diagnosis → Reduced inpatient days High diagnostic accuracy → Lower misdiagnosis risk Software upgrades → Extended equipment lifecycle Field Strength Matters: Ultra-High-Field MRI Is the Future The market is categorized by field strength: Low-to-mid-field High & very-high-field Ultra-high-field Among these, ultra-high-field MRI is experiencing the highest CAGR. These systems offer: Superior Signal-to-Noise Ratio (SNR) Enhanced contrast resolution Exceptional neuro and cardiovascular imaging As hospitals seek competitive clinical differentiation, ultra-high-field MRI investments will become a strategic priority. End User Analysis: Why Hospitals Dominate the Market Hospitals are currently the largest adopters of MRI systems and are expected to continue dominating. Their edge lies in: Access to capital investment budgets Integrated multi-specialty diagnostic care Alignment with value-based reimbursement models For CFOs and CIOs, the integration of MRI into enterprise imaging architecture ensures: Optimized resource allocation Predictable revenue from advanced imaging Better data utilization for AI algorithms Geographical Insights: North America Sets the Pace North America leads the global MRI systems market due to: Cutting-edge healthcare infrastructure Strong presence of OEMs and distributors Favorable regulatory and R&D support Healthcare providers in the U.S. are focusing on: High-throughput MRI centers Remote scanning capabilities Integration with AI and cloud-based radiology tools For OEMs and med-tech investors, the region is ripe for partnerships, pilot programs, and acquisitions. Request Sample Pages : Top Companies to Watch: Strategic Moves from Market Leaders 1. Siemens Healthineers (Germany) A frontrunner with a global manufacturing and R&D footprint, Siemens has deep investments in molecular imaging, AI-driven diagnostics, and portable MRI innovations. 2. GE HealthCare (US) GE's strategic growth is powered by inorganic acquisitions and global reach. Their solutions span molecular imaging, cardiac MRI, and biopharma integration. 3. Philips (Netherlands) Philips focuses on image-guided therapy, ultrasound integration, and cloud-connected platforms. Their Diagnosis & Treatment segment is a growth engine for MRI innovation. Other notable players: Canon Inc. (Japan) FUJIFILM Corporation (Japan) Fonar Corporation (US) Esaote S.p.A (Italy) United Imaging Healthcare (China) Innovation Trends: The Future of MRI is AI, Portability & Cloud Emerging innovation themes include: AI-enhanced image reconstruction Low-helium or helium-free systems Cloud-integrated radiology reporting Portable and point-of-care MRI Strategic Implications for C-suite: AI & ML tools embedded into MRI workflows can increase operational efficiency by 20–30% Cloud PACS integration ensures interoperability across multisite locations Portability introduces new revenue streams in mobile diagnostics and remote care What This Means for Healthcare Decision-Makers For CIOs, CFOs, and Clinical Executives, investing in MRI systems is no longer about hardware—it's a holistic ecosystem decision involving software, analytics, AI, and patient experience. Key Questions Executives Are Asking: How does MRI investment impact long-term patient retention and referral growth? Can we bundle MRI services with AI diagnostics for higher margins? What's the total cost of ownership (TCO) versus projected operational ROI? Conclusion: MRI Systems as a Strategic Differentiator in 2030 As demand for advanced diagnostic capabilities surges globally, MRI systems stand out as a high-impact, high-yield investment. With expanding clinical applications, regulatory support, and innovation momentum, this is an opportunity that healthcare leaders cannot afford to overlook. Whether you're managing hospital procurement, evaluating M&A options in the imaging space, or scaling a diagnostic chain, the MRI systems market offers sustainable ROI, technological resilience, and significant growth potential through 2030. For more information, Inquire Now!
